AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire•06/11/2026•18:00 ET
0
Key Highlights
- ➤CEO Eric Honroth receives 164,121 inducement-award shares at target performance.
- ➤First sign-on award covers 62,928 restricted shares, vesting annually over four years.
- ➤Second sign-on award covers 62,928 target PSUs, with 0%-240% payout range.
- ➤Third sign-on award covers 38,265 restricted shares, vesting in 2027 and 2028.
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the Company effective as of November 2, 2026.
Get started
Create a free account to read the full story.